Dr. Revathi Angitapalli, MD

Dr. Angitapalli practices at The Center for Cancer and Blood Disorders - Fort Worth (Magnolia Ave) in Fort Worth, Texas.

Dr. Angitapalli's NPI, 1497921829, was assigned on May 6, 2008. Dr. Angitapalli graduated from Kurnool Medical College in 2000. Dr. Angitapalli holds Texas license M7828.

Dr. Angitapalli's primary practice is The Center for Cancer and Blood Disorders - Fort Worth (Magnolia Ave), at 800 W Magnolia Ave, Fort Worth, TX 76104 in Tarrant County. The practice phone is (817) 759-7000.

Dr. Angitapalli's primary practice is The Center for Cancer and Blood Disorders - Fort Worth (Magnolia Ave) in Fort Worth, Texas. Dr. Angitapalli is also affiliated with Baylor Scott & White Institute for Rehabilitation - Dallas. The medical group on file is The Center for Cancer and Blood Disorders. Dmand AI also links Dr. Angitapalli to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Angitapalli practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Angitapalli's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Angitapalli is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Angitapalli's licenses on file in 2 states: Texas and New York.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Angitapalli treats.

CMS data shows 67,579 Medicare services from Dr. Angitapalli across 30 procedure codes in 2024, for 381 Medicare patients. Medicare paid $347,920 for them.

CMS counts 381 Medicare patients who saw Dr. Angitapalli in 2024. The largest group is 65 to 74, with 192 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Angitapalli's median patient age at 66, with 77% women.

In 2024, Dr. Angitapalli wrote 1,370 Medicare Part D claims for 318 patients. 73% of them were for generic drugs. CMS names the drug for 1,133 of them, across 28 drugs with 11 or more claims each, at $2,489,551 in total drug cost. In 2023, CMS named 670 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Dr. Angitapalli for performance year 2024, reported as part of a group. Dr. Angitapalli accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Angitapalli as offering telehealth.

Dmand AI links 2 papers to Dr. Angitapalli, published from 2006 to 2009. Dr. Angitapalli's most frequent co-authors are Sundar Jagannath, MD and Amitabha Mazumder, MD.

CMS Open Payments shows 1,133 general payments to Dr. Angitapalli from 87 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 82% of the total. Novartis Pharmaceuticals Corporation paid the most, $3,964.

Dr. Angitapalli graduated from Kurnool Medical College in 2000.

Dr. Angitapalli is in network with 19 carriers, including Elevance, Aetna and United Healthcare. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.